Myeloproliferative neoplasms (MPNs) are hematological diseases that are driven by somatic mutations in hematopoietic stem and progenitor cells. These mutations include JAK2, CALR and MPL mutations as the main disease drivers, mutations driving clonal expansion, and mutations that contribute to progression of chronic MPNs to myelodysplasia and acute leukemia. JAK-STAT pathway has played a central role in the disease pathogenesis of MPNs. Mutant JAK2, CALR or MPL constitutively activates JAK-STAT pathway independent of the cytokine regulation. Symptomatic management is the primary goal of MPN therapy in ET and low-risk PV patients. JAK2 inhibitors and interferon-α are the established therapies in MF and high-risk PV patients.
Introduction
MPNs are one of the major disease categories of chronic hematological malignancies. Like other hematological disorders, MPNs are characterized by somatic mutations that occur in HSPCs, which lead to clonal expansion and excessive production of mature blood cells. As a myeloid disease, hyperplasia of differentiated blood cells in MPN is mainly restricted to myeloid lineages including erythrocytes, megakaryocytes and granulocytes [1, 2] . Among sub-categories of MPNs, chronic myelogenous leukemia (CML) distinguishes itself from others by a predominant translocation mutation known as BCR-ABL or Philadelphia chromosome. BCR-ABL is the driver mutation in the majority of CML cases and the presence of this mutation shapes the diagnosis and treatment of the disease [3] [4] [5] . BCR-ABL-negative MPNs consist of polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), not otherwise specified (NOS) and unclassifiable MPNs. PV, ET and PMF together are also classified as classical MPNs. PV is characterized by excessive production of progenitors and mature cells of the erythroid lineage. ET is featured with hyperplasia of megakaryocytic lineage. PMF is a more aggressive disease than PV and ET with bone marrow fibrosis and megakaryocytic lineage expansion as main features [2] .
The genetic basis of classical MPNs has been extensively studied. A single amino acid mutation of Janus kinase 2 (JAK2), named JAK2V617F mutation, is present in more than 95% of PV patients and over 50% of ET and PMF patients [6] [7] [8] [9] . Mutations in exon 12 of JAK2 gene have also been identified in the majority of JAK2V617F-negative PV patients as the disease drivers [10] . CALR mutations are the second most frequent mutations following JAK2V617F and are present in 25-35% of ET and PMF patients [11, 12] . Mutations of thrombopoietin receptor (MPL) are the other main disease driver that contributes to 3-5% of ET and PMF [13, 14] . The three mutations occur in an almost mutually exclusive way, although few cases of co-occurrence have been reported [15] [16] [17] [18] . Patients who carry none of these three mutations are reported to be polyclonal and classified as "Triple negative" patients [19] (Fig. 1) .
Apart from JAK2, CALR and MPL mutations, many other mutations contribute to MPN phenotype and the disease heterogeneity. Although most of them are not MPN specific, these mutations are believed to play roles in different stages of MPN development including the initiation of clonal hematopoiesis, disease progression to secondary myelofibrosis and leukemic transformation ( Fig. 2) [20] [21] [22] . Multiple epigenetic regulators have been identified to carry somatic mutations in MPN patients such as TET2, DNMT3A, IDH1/2, PRC1/2, ASXL1 and EZH2 [20] [21] [22] [23] . These genes are involved in the regulation of DNA methylation and histone modification [21] . Several of these mutations, for instance TET2 and DNMT3A, are believed to cause clonal hematopoiesis which can be the prior step to establish MPN and other hematological malignancies. The term "clonal hematopoiesis of indeterminate potential" (CHIP) is used to describe this process [24] [25] [26] . Both DNMT3a and EZH2 mutations have been shown to induce myelofibrosis phenotype in mice in the presence of JAK2V617F mutation [27] [28] [29] . Mutations of transcription factors such as TP53, CUX1, RUNX1 are also among the frequent recurrent mutations of the disease. TP53 mutation has been associated with leukemic transformation and poor prognosis of the MPN patients [30, 31] . Mutations of splicing factors, particularly SF3B1 and SRSF2, also occur in the cohort of MPN patients [32] .
Disease driver mutations in MPN
JAK2 mutation JAK2 kinase belongs to the Janus kinase family consisting of JAK1, JAK2, JAK3 and TYK2. JAK2 knockout mice are embryonic lethal due to the defects in hematopoiesis [33, 34] . Conditional knockout of the gene in adult mice causes impairment in erythropoiesis and thrombopoiesis as well as compromised development of monocytic and granulocytic lineages, suggesting its indispensable role in myeloid hematopoiesis [35] . As the most frequent somatic mutation present in BCR-ABL-negative MPNs, JAK2V617F occurs as a G to T point mutation in exon 14 of JAK2 gene. The mutation substitutes a valine with phenylalanine in the pseudokinase domain of the JAK2 kinase, blocking its autoinhibitory effect and therefore constitutively activates the JAK2 kinase independent of cytokine binding [6] [7] [8] [9] . JAK2V617F mutation occurs in the HSCs and gives rise to the clonal expansion and overproduction of the myeloid hematopoietic cells. The mutation was occasionally found in lymphoid cells [36, 37] . Although primarily present as heterozygous mutation, JAK2V617F acquires homozygosity through a mitotic recombination event known as uniparental disomy (UPD) at a locus on chromosome 9p in a subset of the patients [38] . Given that JAK2V617F is the main driver in PV, ET and PMF, it is intriguing how one mutation leads to different subtypes of MPN diseases. The underlying mechanism is still elusive. JAK2V617F allele burden has been linked to the distinct disease phenotypes, as ET patients tend to have low burden (around 25% or lower) and PV patients tend to have higher burden (around 50% or higher). Secondary PV and ET patients are often to be fully clonal [39] [40] [41] . This correlation is also revealed in transgenic mice model, as mice with high copy number of JAK2V617F tend to show PV phenotype [42] .
JAK2V617F mutation requires the association with type-I cytokine receptors to confer its oncogenic activation, suggested by both in vitro and in vivo studies [43] [44] [45] . Erythropoietin receptor (EPOR), granulocyte colony-stimulating factor receptor (GCSFR) and MPL are the main candidates activated by the JAK2 mutation, resulting in the expansion of erythroid, granulocytic and megakaryocytic lineages, respectively. The mutant JAK2 kinase activates signal transducer and activator of transcription (STAT) proteins, phosphotidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and mitogen activated protein kinase (MAPK)-related pathways [46] . It seems that different components of these pathways contribute to the disease development differently. The importance of STAT5 in the JAK2V617F driven MPN has been addressed in the mouse model, as the disease phenotype is lost when STAT5 is genetically ablated [47] . In contrast, the ablation of STAT3 results in the exacerbation of the disease in mice model, reported by Yan and colleagues [48] . STAT1 activity, on the other hand, has been implicated as a molecular switch between the ET or PV phenotype in MPN patients [49] . Additionally, a few studies showed synergistic effect was achieved when combinatorial inhibition of JAK2 kinase together with PI3K/mTOR pathway was applied, suggesting that multiple pathways might have crosstalks in driving the disease [50] [51] [52] [53] .
Other than V617F mutation, JAK2 exon 12 mutations occur at residues between 537 and 543 located at the linker between SH2 and pseudokinase domain [10] . They also lead to a constitutive activation of JAK2 kinase and a hyperplasia in erythroid lineage. In comparison to V617F mutation, the disease phenotype driven by the exon 12 mutations seems to be more restricted to the erythroid lineage of the patients, as these mutations have only been reported in PV patients but not in ET and PMF patients [10] . Patients carrying JAK2 exon 12 mutations tend to have lower leukocytosis and thrombocytosis than the ones with V617F mutation [54] . and CALR mutations account for the vast majority of the classical MPN cases. JAK2 kinase is a tyrosine kinase with a length of 1132 amino acids. It consists of 4 functional domains including a FERM domain to mediate the binding with receptors, a SH2-like domain for binding of phosphorylated tyrosine peptides, a pseudokinase domain for regulatory function of the kinase activity and an ATP binding kinase domain. The pseudokinase domain plays a negative regulatory role in the kinase activity and it is where the mutation V617F localizes. Thrombopoietin receptor MPL has 635 amino acids, consisting of an extracellular domain (ECD), a transmembrane domain (TMD) and a cytosolic domain (CD). A signal peptide is located at the first 25 amino acids at N-terminus. 4 N-linked glycosylation sites are identified at the ECD of the protein which mediate the trafficking of the receptor. Although the crystal structure of the receptor is not resolved, predication of the structure could be obtained through the sequences in homology with other type-1 cytokine receptors. TMD and the adjacent amphipathic helical RWQFP motif block the activation of the receptor without the cytokine. Box1 motif at the CD is required for the docking and activation of JAK2. The activation of the receptor requires homodimerization like the other type-1 cytokine receptors such as EPOR and GM-SCF receptor. Human CALR consists of 417 amino acids, containing an N-terminal ER signal peptide, an N-domain, a P-domain, a C-domain and an ER-retention signal (KDEL) at C-terminus. The globular lectin domain has a jelly-roll structure with two anti-parallel β-sheets formed by the N-domain and part of the C-domain. 4 amino acids at the N-domain form interaction with Ca 2+ ions, which is important for maintaining the secondary structure of the protein. An intra-molecular disulfide bond is formed between C105 and C137, leaving a free cysteine (C163) which might be involved in the inter-molecular interaction. The P-domain is proline rich and has an extended arm-like structure, revealed by the NMR study (147). It is where the oxidoreductase ERp57 binds and is crucial for the molecular chaperone function. The C-terminus of calreticulin contains several stretches of negative charged amino acids that bind to Ca 2+ with high capacity, serving as the structure basis of the Ca 2+ buffering function of the protein. The last 4 amino acids KDEL makes an ER retention signal which is responsible for the ER localization of the protein
MPL mutation
As the receptor of TPO, MPL is expressed mainly in HSCs and megakaryocytic lineage. It seems that MPL is not essential for the development of the other hematological lineages as MPL knockout mice have normal blood count except megakaryocytes and platelets [55] . In MPNs, missense mutations of tryptophan 515 at the boundary of the transmembrane domain and the cytosolic domain of MPL are the mutation hotspot in ET and PMF patients. The most common mutation is W515L followed by W515R [13, 14] . Other missense mutations at the same position also occur in a small cohort of patients. Serine 505 in the transmembrane is another site where mutations are identified in MPN, although the frequency is much lower [56] . All these mutations are located at the RWQFP motif or the transmembrane domain (TMD), leading to cytokine-independent activation of the receptor and the downstream JAK-STAT pathway. Unlike JAK2V617F and CALR mutations, no knock-in mouse model for MPL mutations has been described. Instead, retroviraltransduced transplantation model suggests an ET to MF phenotype which also significantly reduce the life expectancy of the animals [21] .
CALR mutation
Wild-type calreticulin is a 46-kDa protein located primarily in endoplasmic reticulum (ER) lumen. The main functions of calreticulin include the maintenance of calcium (Ca 2+ ) homeostasis in the ER and the molecular chaperone function in the quality control of protein folding [57] [58] [59] . Calreticulin contains several stretches of negatively charged sequences at C-terminus that bind to Ca 2+ at high capacity [60, 61] . Its molecular chaperone function relies on its N-glycan binding domain and its vicinity to interact with glycosylated or non-glycosylated proteins [62] . Calreticulin and its ER membrane-bound homologs calnexin create calreticulin/calnexin cycle for the quality control of N-linked glycosylated proteins [58, 63, 64] .
MPN-associated CALR mutations are insertions and deletions located at the exon 9 of CALR gene, all leading to the (− 1/+ 2) frameshift mutation and generating a novel mutant specific C-terminal peptide sequence [11, 12] . Deletion of 52 bp (del52; also called type-I) and insertion of 5 bp (Ins5; also called type-II) are the most frequent mutation types identified in approximately 85% of CALR patients. The rest of CALR mutations can be categorized into type-Ilike or type-II-like mutations. The mutations substitute the C-terminal acidic residues of calreticulin with an arginine/ lysine-rich basic peptide and remove the KDEL ER retention sequence [11, 12] . Heterozygous mutations are the predominant in clinical cases and very few patients carry homozygous CALR mutations. The majority of homozygous mutations are the type-II mutation and they are associated with the syndrome of the acquired myeloperoxidase (MPO) deficiency in MPN patients [65] . Type-I mutations have higher penetrance of PMF, but PMF patients with type-I mutations have better prognosis than those with JAK2 or type-II CALR mutations [66] [67] [68] . CALR-positive patients also tend to have higher allele burden than JAK2 patients, suggesting the CALR mutation might be a stronger clonal driver than JAK2 mutation.
Like JAK2 and MPL mutations, CALR mutations also drive MPN disease by activating JAK-STAT pathway. STAT5 luciferase reporter assay in JAK2-deficient γ2A cells and cytokine-independent growth of BaF3 cell lines have been used as the most common in vitro models to study cytokine signaling. It has been shown that mutant calreticulin depends on MPL for its activity, as both mutant CALRinduced STAT5 activation and cytokine-independent growth of Ba/F3 cells require the presence of MPL [69] [70] [71] [72] [73] [74] . This also explains why CALR mutations are only present in ET and PMF patients but not in PV patients, as MPL is mainly expressed in megakaryocytic lineage. Interestingly, when mutated, calreticulin has been found to form a stable complex with MPL and activates it constitutively regardless of cytokine presence [74, 75] . The mechanism of how this interaction is formed still requires further investigation, but a couple of discoveries have helped to elucidate this. Firstly, the binding and activation of MPL by mutant calreticulin require its N-glycan binding domain, as glycan-deficient CALR del52 is unable to activate JAK-STAT pathway [69] . Several studies also show that this protein-protein interaction could not be maintained when certain amino acid residues at this domain is mutated [75] [76] [77] . Secondly, mutant calreticulin has been shown to undergo homomultimerization through its mutant specific C-terminus and they interact with MPL as multimers [78] . Elf and colleagues also showed that the positive charge rather than the actual amino acid sequence of the mutated C-terminal tail is the key for the oncogenic activation, as substitution of lysine and arginine residues with glycine abrogates its activity, whereas changing the neutral residues does not show such an effect [73] .
The localization of mutant calreticulin is also intriguing. Mutant calreticulin loses its ER retention signal due to the mutation at the C-terminus. It enters a secretary pathway and is primarily localized in the Golgi apparatus and further traffics to the cell membrane [69, 76, 77, 79] . Cell surface localization of MPL-CALR complex has been detected and is shown to be essential for the oncogenic activity [76, 77] . Also, the N-terminal ER signal peptide is required for the oncogenic function of mutant calreticulin too, suggesting that the MPL-CALR interaction is initiated in the ER [76] (Fig. 3) .
Several mutant Calr mice models have also been established, all exhibit an ET-like phenotype [80] [81] [82] [83] . Myelofibrosis phenotype was observed only in the homozygous Calr mutant mice model [81] . The germline homozygous Calr del52 mice are embryonic lethal due to developmental deficiency in the ventricular walls [83] . Intriguingly, only the CRISPR-Cas9-generated germline Calr del52 mice show competitive advantage of mutant clones over wild-type clones in the transplantation assay [83] . Neither Shida nor Li's mice model shows such phenomenon [80, 81] .
Overview of MPN therapy
MPN patients suffer from various disease symptoms such as fatigue, inactivity and weight loss, a higher risk of thrombotic and hemorrhagic events, disease progression to secondary myelofibrosis and leukemia. Patients, in particular those with MF and high-risk PV, also have reduced life expectancy [84] [85] [86] [87] .
For low-risk PV and ET patients, since the diseases are in the chronic phase and are not directly associated with reduced survival, the treatment has been focused on symptomatic management, notably thrombosis and hemorrhage. Low-dose aspirin, phlebotomy and cytoreductive drugs have been used for this purpose for decades in the clinic. Among the cytoreductive drugs, hydroxyurea (HU) shows its superiority over pipobroman and busulfan, as the latter two drugs have proven to induce the risk of leukemic transformation [88] [89] [90] .
In contrast to PV and ET, MF is a more aggressive disease with severe symptoms such as splenomegaly and anemia. Both life quality and expectancy are compromised in MF patients, which raised the need for more effective treatment. Allogeneic stem cell transplantation (allo-SCT) is the only curative treatment for MF, but carries a risk of graftrelated complications and even mortality [91] .
Since JAK2 mutation is the predominant driver of MPNs and JAK-STAT pathway is the causative signaling of the diseases, developing effective JAK2 inhibitors has raised major interests in the field. Ruxolitinib, the JAK1/2 kinase inhibitor, received the approval as the first-line therapy in MF treatment based on the clinical findings from COM-FORT I/II trials [92, 93] . Ruxolitinib was proven to be effective in reducing splenomegaly and alleviating constitutional symptoms of MF patients. Long-term follow-up studies suggested that ruxolitinib treatment reduced mutant allele burden and showed survival benefits in some patients [94] [95] [96] [97] [98] . The promising clinical data in the PV cohorts lead to the approval of ruxolitinib as the second-line therapy in PV patients who failed to benefit from HU treatment [99] [100] [101] [102] . Despite its success in clinics, one should keep in mind that the drug is designed to target the kinase domain of both JAK1 and JAK2 kinase with no evidence of superior affinity against JAK2V617F mutant [103, 104] . Patients treated with ruxolitinib also rarely achieve complete molecular remission [94] [95] [96] 98] .
Interferon-α (IFNα) has emerged as a promising treatment in MPN. Pegylated IFNα (peg-IFNα) has effectively improved its usage tolerance and achieved high response rates of both hematological and molecular remission in MPN patients [105] [106] [107] [108] [109] [110] . Of a particular note is the high molecular response rate of reducing allele burden in JAK2V617F positive patients treated with IFNα, suggesting that the treatment selectively targets JAK2 mutant clones. However, in CALR-positive patients, although the treatment of peg-IFNα achieves a comparable hematological response in comparison with JAK2V617F positive patients, the molecular remission was significantly compromised based on the data from two studies [111, 112] . On the other hand, in another clinical study, peg-IFNα used at a higher dose did significantly reduce CALR allele burden, suggesting that CALR-positive patients are less sensitive to IFNα treatment compared to JAK2V617F patients [113] . A recent study suggested that the enhanced sensitivity of JAK2V1617F mutated cells to IFNα treatment was due to high expression and phosphorylated level of STAT1 [111] . Additionally, non-driver mutations in MPN also affect the response of the patients to IFNα treatment. For instance, two studies reported that MPN clones harboring TET2 mutation showed resistance to IFNα treatment [107, 114] .
The mechanism of how IFNα achieves such efficacy in MPN patients is still elusive, but a few studies have shown that the cause of malignant stem cell exhaustion is a major contributing factor to the eradication of malignant clones [105, [115] [116] [117] [118] . IFNα induces the HSCs to enter the cycling phase and promote their proliferation and apoptosis. As a result, the HSCs lose their pluripotency to repopulate the hematopoietic system and are depleted over time [115, 116] . In the JAK2V617F-positive MPN context, IFNα preferentially targets the malignant clones and deprives them of the growth advantage over the wildtype clones. Furthermore, the IFNα-treated JAK2V617F mutated stem cells are unable to induce MPN disease phenotype, shown by the secondary transplantation assay in the murine models [118] . Fig. 3 The molecular pathogenesis of JAK2, CALR and MPL mutations in MPNs. JAK-STAT pathway plays a central role in hematopoiesis and MPN pathogenesis. In the normal physiological process, Upon induction by cytokines such as EPO, TPO and GM-SCF, cytokine receptors dimerize and activate JAK2. The activated JAK2 phosphorylates and activates STAT1/3/5 as well as (PI3K)/AKT/mTOR and MAPK pathways. STAT molecules translocate into the nucleus and activate the corresponding genes as transcription factors.
In the MPN disease model, JAK2, CALR and MPL mutations constitutively activate these pathways regardless of the cytokine activation
Perspective
The discovery of the disease-associated somatic mutations, in particular JAK2, CALR and MPL mutations, has clarified the genetic basis of MPNs. Despite this, MPN therapies have not sufficiently exploited our genetic knowledge of the diseases. Although developing novel therapies in MPN patients remains to be challenging, the progress made on the molecular pathogenesis of the driving mutations paved the way to emerging novel therapies that can selectively target the malignant clones.
